Emergent BioSolutions Inc. (NYSE:EBS) Shares Sold by Shell Asset Management Co.

Shell Asset Management Co. lowered its position in shares of Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) by 16.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 8,243 shares of the biopharmaceutical company’s stock after selling 1,673 shares during the quarter. Shell Asset Management Co.’s holdings in Emergent BioSolutions were worth $97,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of EBS. Covestor Ltd boosted its holdings in shares of Emergent BioSolutions by 43.8% in the 1st quarter. Covestor Ltd now owns 1,612 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 491 shares during the last quarter. Baird Financial Group Inc. boosted its holdings in shares of Emergent BioSolutions by 9.1% in the 1st quarter. Baird Financial Group Inc. now owns 7,313 shares of the biopharmaceutical company’s stock valued at $300,000 after purchasing an additional 607 shares during the last quarter. Centaurus Financial Inc. boosted its holdings in shares of Emergent BioSolutions by 19.6% in the 1st quarter. Centaurus Financial Inc. now owns 3,796 shares of the biopharmaceutical company’s stock valued at $156,000 after purchasing an additional 621 shares during the last quarter. Guggenheim Capital LLC boosted its holdings in shares of Emergent BioSolutions by 0.8% in the 1st quarter. Guggenheim Capital LLC now owns 85,792 shares of the biopharmaceutical company’s stock valued at $3,522,000 after purchasing an additional 680 shares during the last quarter. Finally, Ancora Advisors LLC acquired a new position in shares of Emergent BioSolutions in the 1st quarter valued at $66,000. Institutional investors and hedge funds own 80.44% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. JPMorgan Chase & Co. reiterated an “underweight” rating and issued a $9.00 price target (down previously from $23.00) on shares of Emergent BioSolutions in a report on Friday, March 17th. Benchmark raised shares of Emergent BioSolutions from a “hold” rating to a “buy” rating and set a $22.00 target price on the stock in a research note on Monday, April 10th. TheStreet downgraded shares of Emergent BioSolutions from a “c-” rating to a “d” rating in a research note on Monday, February 27th. Finally, StockNews.com began coverage on shares of Emergent BioSolutions in a research note on Thursday, March 16th. They issued a “sell” rating on the stock. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $28.00.

Emergent BioSolutions Stock Performance

Emergent BioSolutions stock opened at $9.18 on Friday. Emergent BioSolutions Inc. has a 12-month low of $7.74 and a 12-month high of $40.45. The company has a market capitalization of $462.67 million, a price-to-earnings ratio of -2.05 and a beta of 0.93. The company has a debt-to-equity ratio of 0.32, a current ratio of 0.98 and a quick ratio of 0.70. The firm’s fifty day moving average price is $9.89 and its 200 day moving average price is $12.42.

Emergent BioSolutions (NYSE:EBS – Get Rating) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($3.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.67) by ($1.50). Emergent BioSolutions had a negative return on equity of 7.57% and a negative net margin of 19.97%. The firm had revenue of $165.10 million for the quarter, compared to analysts’ expectations of $142.85 million. During the same period last year, the firm earned $0.18 EPS. The business’s quarterly revenue was down 46.3% on a year-over-year basis. On average, research analysts forecast that Emergent BioSolutions Inc. will post -1.23 EPS for the current fiscal year.

Emergent BioSolutions Company Profile

(Get Rating)

Emergent BioSolutions Inc engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm’s products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV.